Former entertainer wins in appeal against joint compound manufacturer
November 9, 2009 (SAN FRANCISCO) –Baron & Budd, P.C. announced an appellate victory in an asbestos cancer lawsuit brought on behalf of mesothelioma patient Joan Mahoney and her husband Daniel Mahoney. Baron & Budd attorneys showed that Mrs. Mahoney’s mesothelioma was caused by her exposure to Georgia Pacific’s asbestos-containing joint compound and that Georgia Pacific knew before Mrs. Mahoney’s exposure that asbestos in its product could caused disease.
Mrs. Mahoney, a native of San Francisco, spent three decades in show business. Her singing career took her around the world on United Service Organizations (USO) tours seven times. It was her work in a family home-remodeling business, though, that exposed Mrs. Mahoney to Georgia Pacific’s asbestos-containing joint compound. Alongside her husband, Mrs. Mahoney built and remodeled homes during the 1970s, 1980s and 1990s.
Mrs. Mahoney was diagnosed in August 2006 with pleural mesothelioma, an asbestos-related cancer that attacks the membrane around the lungs. At the time of her diagnosis, Mrs. Mahoney was caring for her husband, who had suffered a serious stroke. Mr. Mahoney was paralyzed and could not speak; and Mrs. Mahoney, weakened by her cancer and chemotherapy, was unable to take care of him.
“Georgia Pacific failed to protect Mrs. Mahoney and the many others who used its product,” said Baron & Budd shareholder. “I am pleased that Georgia Pacific will be held accountable for the harm they caused Mrs. Mahoney.”
About Baron & Budd, P.C.
Dallas-based Baron & Budd, P.C., with offices in Baton Rouge, Austin and Beverly Hills, is a nationally recognized firm with more than three decades of experience representing people and communities harmed by corporate negligence. It has been recognized by the National Law Journal’s “Plaintiffs’ Hot List” in 2002-2006 and 2008 (Incisive Media). The firm resolved one of the first asbestos cases in the United States in the 1970s and continues to serve people diagnosed with mesothelioma and asbestos-related lung cancer, as well as communities and consumers dealing with the costs of fraud and corporate misconduct.